RxDoctor Payments Data

Thomas Jenkins, MD

Ophthalmology · Richmond, VANPI 1114345634

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $16,912 of the $25,904 with a category attached, or 65.3%. Regeneron Healthcare Solutions, Inc. accounts for 64.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $9,701 and has fallen 61.2% since, to $3,762 in 2025. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,904in general payments, 2019–2025

Across 31 payments — averaging $835.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$17K
  • Genentech USA, Inc.$7K
  • Regeneron$806
  • Alimera Sciences, Inc.$596
  • AbbVie$196
  • Alcon$136
  • plus $329 from 5 others

What the payments were for

  • Consulting fees$5,94023%
  • Speaking & faculty fees$16,91265%
  • Travel & lodging$1,5876%
  • Food & beverage$1,4656%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,904 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$4,860,197
Medicare patients
1,536
Services billed
35,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate236$7,842
Ofloxacin120$1,294
Ketorolac Tromethamine68$1,143
Brimonidine Tartrate11$773
Atropine Sulfate12$403
Latanoprost29$282
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat14$239
Timolol Maleate12$84

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →